Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
Expert Review of Neurotherapeutics
|
July 9, 2019
Esketamine for treatment resistant depression
Jennifer Swainson, Rejish K Thomas, Shaina Archer, et al.
Therapeutic Advances in Drug Safety
|
June 23, 2025
Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee
Gilmar Gutierrez, Gustavo Vazquez, Nisha Ravindran, et al.
BMJ Open
|
December 29, 2022
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
Gustavo Vazquez, Gilmar Gutierrez, Joshua Rosenblat, et al.
Psychiatry Research
|
August 11, 2024
IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran, et al.
Journal of Psychiatric Research
|
May 27, 2022
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Neuroscience and Biobehavioral Reviews
|
April 17, 2025
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
Shakila Meshkat, Gunjan Malik, Richard J Zeifman, et al.
CNS Spectrums
|
May 26, 2025
Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications
Kayla M Teopiz, Heidi K Y Lo, Moiz Lakhani, et al.
Brain and Behavior
|
July 10, 2025
Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review
Shakila Meshkat, Corinna Di Luciano, Alyssa Swiderski, et al.
Psychopharmacology
|
July 1, 2026
Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review
Sarah Ann Smith, Haseeb Mohammad, Lik Hang N Lee, et al.
Journal of Clinical Medicine
|
March 17, 2025
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Shakila Meshkat, Taha Malik, Richard Zeifman, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
Expert Review of Neurotherapeutics
|
July 9, 2019
Esketamine for treatment resistant depression
Jennifer Swainson, Rejish K Thomas, Shaina Archer, et al.
Therapeutic Advances in Drug Safety
|
June 23, 2025
Abuse liability for esketamine in a cohort of patients undergoing an acute treatment course to manage treatment-resistant depression: a secondary analysis of an observational study in real-world clinical practicee
Gilmar Gutierrez, Gustavo Vazquez, Nisha Ravindran, et al.
BMJ Open
|
December 29, 2022
Association of intranasal esketamine, a novel 'standard of care' treatment and outcomes in the management of patients with treatment-resistant depression: protocol of a prospective cohort observational study of naturalistic clinical practice
Gustavo Vazquez, Gilmar Gutierrez, Joshua Rosenblat, et al.
Psychiatry Research
|
August 11, 2024
IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression
Gilmar Gutierrez, Jennifer Swainson, Nisha Ravindran, et al.
Journal of Psychiatric Research
|
May 27, 2022
The abuse liability of ketamine: A scoping review of preclinical and clinical studies
Tuyen T Le, Isabel Pazos Cordero, Muhammad Youshay Jawad, et al.
Neuroscience and Biobehavioral Reviews
|
April 17, 2025
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review
Shakila Meshkat, Gunjan Malik, Richard J Zeifman, et al.
CNS Spectrums
|
May 26, 2025
Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications
Kayla M Teopiz, Heidi K Y Lo, Moiz Lakhani, et al.
Brain and Behavior
|
July 10, 2025
Efficacy and Safety of Glucagon-Like Peptide-1 Agonists for Psychiatric Symptoms: A Systematic Review
Shakila Meshkat, Corinna Di Luciano, Alyssa Swiderski, et al.
Psychopharmacology
|
July 1, 2026
Investigating the impact of serotonergic psychedelic drugs, MDMA and ketamine on social cognition in psychiatric disorders: A scoping review
Sarah Ann Smith, Haseeb Mohammad, Lik Hang N Lee, et al.
Journal of Clinical Medicine
|
March 17, 2025
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Shakila Meshkat, Taha Malik, Richard Zeifman, et al.
Page
of 4